Gut Microbiota and Alzheimer's Diseases
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03827733|
Recruitment Status : Recruiting
First Posted : February 1, 2019
Last Update Posted : April 9, 2019
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||Gut Microbiota and Alzheimer's Diseases|
|Actual Study Start Date :||February 1, 2018|
|Estimated Primary Completion Date :||December 31, 2019|
|Estimated Study Completion Date :||December 31, 2020|
Participants who are diagnosed with AD.
Spouse of the AD patients
Spouse of AD patients, and live together with AD patients.
Elderly participants with normal congition
Community dwelling elderly with normal cognition .
- Gut amyloid-beta 42 [ Time Frame: within 1 year after the participants was assessed ]Gut amyloid-beta 42 will be determined by elisa, BCA, western blot,.etc.
Biospecimen Retention: Samples Without DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03827733
|Contact: Yuan Shen, MD, PhDfirstname.lastname@example.org|
|Contact: Zhongyong Shi, MDemail@example.com|
|Shanghai Tenth People's Hospital||Recruiting|
|Shanghai, Shanghai, China, 200072|
|Contact: Yanxia Guo, M.D. 021-65982875 firstname.lastname@example.org|
|Principal Investigator:||Yuan Shen, MD, PhD||Shanghai 10th People's Hospital|